Hostname: page-component-5447f9dfdb-cjbmw Total loading time: 0 Render date: 2025-07-28T09:45:15.123Z Has data issue: false hasContentIssue false
  • English
  • Français

The economic burden of depression in Sweden from 1997 to 2005

Published online by Cambridge University Press:  16 April 2020

Patrik Sobocki ,
Ingrid Lekander ,
Fredrik Borgström ,
Oskar Ström  and
Bo Runeson
Patrik Sobocki*
Affiliation:
Division for International Health (IHCAR), Karolinska Institutet, Stockholm, Sweden. European Health Economics, Vasagatan 38, SE-111 20, Stockholm, Sweden
Ingrid Lekander
Affiliation:
European Health Economics, Vasagatan 38, SE-111 20, Stockholm, Sweden
Fredrik Borgström
Affiliation:
European Health Economics, Vasagatan 38, SE-111 20, Stockholm, Sweden
Oskar Ström
Affiliation:
European Health Economics, Vasagatan 38, SE-111 20, Stockholm, Sweden
Bo Runeson
Affiliation:
Department of Clinical Neuroscience, Section for Psychiatry, St. Göran's Hospital, Karoliniska Institutet, SE-171 76, Stockholm, Sweden
*
*Corresponding author. European Health Economics, Vasagatan 38, SE-11120 Stockholm, Sweden. Tel.: +46 8 545 28 548; fax: +46 8 545 28 549. E-mail address:patrik.sobocki@ki.se (P. Sobocki).
Get access

Abstract

Background

Depression is one of the most common causes of disability and is associated with substantial reductions in the individual's quality of life. The aim of this study was to estimate the economic burden of depression to Swedish society from 1997 to 2005.

Materials and Methods

The study was conducted in a cost-of-illness framework, measuring both the direct cost of providing health care to depressive patients, and the indirect costs as the value of production that is lost due to morbidity or mortality. The costs were estimated by a prevalence and top-down approach.

Results

The cost of depression increased from a total of €1.7 billion in 1997 to €3.5 billion in 2005, representing a doubling of the burden of depression to society. The main reason for the cost increase is found in the significant increase in indirect costs due to sick leave and early retirement during the past decade, whereas direct costs were relatively stable over time. In 2005, indirect costs were estimated at €3 billion (86% of total costs) and direct costs at €500 million (16%). Cost of drugs was estimated at €100 million (3% of total cost).

Conclusion

The cost of depression is substantial to society and the main cost driver is indirect costs due to sick leave and early retirement. The cost of depression has doubled during the past eight years making it a major public health concern for the individuals afflicted, carers and decision makers.

Keywords

CostCost of illnessEconomic burdenDepressionSweden

Information

Type
Epidemiology and Social Psychiatry
Information
European Psychiatry , Volume 22 , Issue 3 , April 2007 , pp. 146 - 152
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Andlin-Sobocki, P.Jonsson, B.Wittchen, H.U.Olesen, J.Cost of disorders of the brain in Europe. Eur J Neurol 2005;12 Suppl. 1):1–27.10.1111/j.1468-1331.2005.01202.xCrossRefGoogle ScholarPubMed
Andlin-Sobocki, P.Wittchen, H.U.Cost of affective disorders in Europe. Eur J Neurol 2005;12(Suppl. 1):34–38.10.1111/j.1468-1331.2005.01195.xCrossRefGoogle ScholarPubMed
Apoteket, Svensk Läkemedelsstatistik 2000. Stockholm: Apoteket; 2000. (Swedish Drug Statistics 2000).Google Scholar
Bodlund, O.[Most depressed patients can be treated in primary health care]. Lakartidningen 2000;97:1244–1249.Google Scholar
Bolin, KJacobson, L.Depression och ångest: De samhällsekonomiska kostnaderna. In Pfizer Health Economic Working Paper Series. Pfizer AB, 2001.Google Scholar
Burström, K.Johannesson, M.Diderichsen, F.Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621–635.10.1023/A:1013171831202CrossRefGoogle ScholarPubMed
Chisholm, D.Diehr, P.Knapp, M.Patrick, D.Treglia, M.Simon, G.Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry 2003;183:121–131.10.1192/bjp.183.2.121CrossRefGoogle Scholar
Drummond, M.O'Brien, B.Stoddart, G.Torrance, G.Methods for the economic evaluation of health care. Boston: Kluwer Academic Publishers; 1997.Google Scholar
Drummond, M.O'Brien, B.Stoddart, G.Torrance, G.Methods for the economic evaluation of health care. ed. 3Oxford: Oxford University Press; 2005.Google Scholar
EuroQol-group EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990 199–208.Google Scholar
Försäkringskassan. Långtidssjukskrivna—bakgrund, diagnos och återgång i arbete. Stockholm: Försäkringskassan (Swedish Social Insurance Agency); 2000 p. 11.Google Scholar
Försäkringskassan. Långtidssjukskrivningar för psykisk sjukdom och utbrändhet. Stockholm: Försäkringskassan (Swedish Social Insurance Agency); 2002. p. 4.Google Scholar
Försäkringskassan. Nybeviljade sjukersättningar/aktivitetsersättningar 2003-2004. Stockholm: Försäkringskassan (Swedish Social Insurance Agency); 2003. p. 1.Google Scholar
Försäkringskassan. Långtidssjukskrivna—diagnos, yrke, arbetsgivare och återgång i arbete. Stockholm: Försäkringskassan (Swedish Social Insurance Agency); 2004. p. 7.Google Scholar
Försäkringskassan. Psykiska sjukdomar och stressrelaterade besvär. Stockholm: Försäkringskassan (Swedish Social Insureance Agency); 2004. p. 8.Google Scholar
Försäkringskassan. RFV Statistikinformation. Försäkringskassan (Swedish Social Insurance Agency); Stockholm 2005. p. 6.Google Scholar
Försäkringskassan. Available at: www.forsakringskassan.se [accessed on July 15, 2006].Google Scholar
Greenberg, P.E.Kessler, R.C.Birnbaum, H.G.Leong, S.A.Lowe, S.W.Berglund, P.A.et al.The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003;64:1465–1475.10.4088/JCP.v64n1211CrossRefGoogle ScholarPubMed
Greenberg, P.F.Stiglin, L.E.Finkelstein, S.N.Berndt, E.R.The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405–418.Google ScholarPubMed
Hjalte, K.Hjelmgren, J.Johansson, F.Persson, U.Betalningsviljan för ett kvalitetsjusterat levnadsår—en pilotstudie [Willingness to pay for a quality-adjusted life year—a pilote study]. Lund: Institute of Health Economics; 2005. p. 1.Google Scholar
Henriksson, F.Jönsson, B.Hälsoekonomiska aspekter på depressionssjukdomen. In: SBU, editro. Behandling av depressionssjukdomar. En systematisk litteraturöversikt Stockholm: SBU; 2004. p. 403–436.Google Scholar
Hodgson, T.A.Meiners, M.R.Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:429–462.10.2307/3349801CrossRefGoogle ScholarPubMed
Isacsson, G.Suicide prevention—a medical breakthrough?. Acta Psychiatr Scand 2000;102:113–117.10.1034/j.1600-0447.2000.102002113.xCrossRefGoogle ScholarPubMed
Kind, P.Sorensen, J.The costs of depression. Int Clin Psychopharmacol 1993;7:191–195.10.1097/00004850-199300730-00010CrossRefGoogle ScholarPubMed
Koopmanschap, M.A.Rutten, F.F.van Ineveld, B.M.van Roijen, L.The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171–189.10.1016/0167-6296(94)00044-5CrossRefGoogle ScholarPubMed
Lepine, J.P.Gastpar, M.Mendlewicz, J.Tylee, A.Depression in the community: the first pan-European study DEPRES [Depression Research in European Society]. Int Clin Psychopharmacol 1997;12:19–29.10.1097/00004850-199701000-00003CrossRefGoogle Scholar
Luce, B.R.Elixhauser, A.Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990;6:57–75.10.1017/S026646230000893XCrossRefGoogle ScholarPubMed
Magne-Ingvar, U.Självmordsprocessen och den sociala situationen. Incitament 2000 531–536.Google Scholar
Mattisson, C.Bogren, M.Nettelbladt, P.Munk-Jorgensen, P.Bhugra, D.First incidence depression in the Lundby Study: a comparison of the two time periods 1947-1972 and 1972-1997. J Affect Disord 2005;87:151–160.10.1016/j.jad.2005.04.002CrossRefGoogle ScholarPubMed
Murray, C.J.Lopez, A.D.Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996;274:740–743.10.1126/science.274.5288.740CrossRefGoogle ScholarPubMed
Norinder, A.Nordling, S.Haggstrom, L.[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. Lakartidningen 2000;97:1693–1698 1700.Google Scholar
Persson, U.Hjelmgren, J.[Health services need knowledge of how the public values health]. Lakartidningen 2003;100:3436–3437.Google Scholar
Raisch, D.W.Understanding quality-adjusted life years and their application to pharmacoeconomic research. Ann Pharmacother 2000;34:906–914.10.1345/aph.19314CrossRefGoogle ScholarPubMed
Runeson, B.S.Rich, C.L.Diagnostic and statistical manual of mental disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann Clin Psychiatry 1994;6:181–183.10.3109/10401239409149001CrossRefGoogle Scholar
Runeson, B.Wasserman, D.Management of suicide attempters: what are the routines and the costs?. Acta Psychiatr Scand 1994;90:222–228.10.1111/j.1600-0447.1994.tb01581.xCrossRefGoogle ScholarPubMed
SCB. Available at: www.sbc.se [accessed on August 15, 2006].Google Scholar
SCB, Average monthly salary in the private sector. Stockholm: Statistiska Centralbyån (Statistics Sweden); 2006.Google Scholar
SKL. Stockholm: Swedish Association of Local Authorities and Regions; 2006.Google Scholar
Sobocki, P.Health economics of depression. 2006 Stockholm: Karolinska Institute; Available athttp://diss.kib.ki.se/2006/91-7140-897-5/thesis.pdf.Google ScholarPubMed
Sobocki, P.Ekman, M.Ågren, H.Jönsson, B.Rehnberg, C.A model to assess the cost-effectiveness of antidepressant treatment in depression. Int J Technol Assess Health Care 2006;22:1–9.10.1017/S0266462306051397CrossRefGoogle Scholar
Sobocki, P.Ekman, M.Ågren, H.Jonsson, B.Rehnberg, C.Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 2006;22:469–477.10.1017/S0266462306051397CrossRefGoogle ScholarPubMed
Sobocki, PEkman, MÅgren, HKrakau, IRuneson, BMårtensson, Bet al.Resource-use and costs associated with patients treated for depression in primary care. Eur J Health Econ, in press.Google Scholar
Sobocki, PEkman, MÅgren, HKrakau, IRuneson, BMårtensson, Bet al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health, in press.Google Scholar
Sobocki, P.Jönsson, B.Angst, J.Rehnberg, C.Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87–98.Google ScholarPubMed
Sobocki, P.Ekman, M.Ågren, H.Runeson, B.Jönsson, B.The mission is remission—health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791–798.10.1111/j.1742-1241.2006.00997.xCrossRefGoogle ScholarPubMed
Sobocki, P.Ekman, M.Ågren, H.Runeson, B.Jonsson, B.The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791–798.10.1111/j.1742-1241.2006.00997.xCrossRefGoogle ScholarPubMed
Socialstyrelsen. Registry of causes of death. 2006.Google Scholar
Spitzer, R.L.Williams, J.B.Kroenke, K.Linzer, M.deGruy, F.V. 3rd Hahn, S.R.et al.Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 1994;272:1749–1756.10.1001/jama.1994.03520220043029CrossRefGoogle ScholarPubMed
Stoudemire, A.Frank, R.Hedemark, N.Kamlet, M.Blazer, D.The economic burden of depression. Gen Hosp Psychiatry 1986;8:387–394.10.1016/0163-8343(86)90018-6CrossRefGoogle ScholarPubMed
Svensk Läkemedelsstatistik 2000 (Swedish Pharmaceutical Statistics 2000). In: Apoteket (Association of Swedish Pharmacies); 2000.Google Scholar
Thomas, C.M.Morris, S.Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514–519.10.1192/bjp.183.6.514CrossRefGoogle ScholarPubMed
Torrance, G.Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1–30.10.1016/0167-6296(86)90020-2CrossRefGoogle Scholar
Torrance, G.Measuring QoL in multiple sclerosis: a utility approach. Abstract 47. In: ISTAHC Annual Meeting, Ottawa, Canada; 1998.Google Scholar
WHO, Mental health: New understanding, new hope. Geneva: WHO; 2001. The World Health Report.Google Scholar
WHO, Macroeconomics and health: investing in health for economic development. Geneva: WHO; 2001. Report of the Commission on Macroeconomics and Health.Google Scholar
Wittchen, H.U.Jacobi, F.Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357–376.10.1016/j.euroneuro.2005.04.012CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.